Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study

• Published in: Clinical cancer research Vol. 31; no. 13; pp. 2599 - 2607
• Main Authors: Davis, Lara E., Zhu, Limin, Latour, Emile, McMahon, Nathan, Nishikawa, Go, Choo, Florence, Nusser, Kevin D., Pittsenbarger, Janét, Burch, Reid, Park, Byung, Mills, Gordon B., Davis, Jessica L., Davare, Monika, Ryan, Christopher W.
• Format: Journal Article
• Language: English
• Published: United States 01.07.2025
• Subjects: Adult; Aged; Aminopyridines - administration & dosage; Aminopyridines - adverse effects; Aminopyridines - pharmacokinetics; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Dose-Response Relationship, Drug; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Female; Humans; Male; Middle Aged; Purines - administration & dosage; Purines - adverse effects; Purines - pharmacokinetics; Sarcoma - drug therapy; Sarcoma - mortality; Sarcoma - pathology

Doxorubicin is the first-line treatment for metastatic soft-tissue sarcomas. Ribociclib, a cyclin-dependent kinase 4/6 intargets the retinoblastoma pathway to induce cell-cycle arrest at the G1-S cell-cycle checkpoint. We hypothesized that administering ribociclib prior to doxorubicin to synchronize...